DGAP-News: biolitec AG publishes unaudited financial statement for 2010/2011 - group revenue increases to 35.2 million Euros
(firmenpresse) - DGAP-News: biolitec AG / Key word(s): Statement
biolitec AG publishes unaudited financial statement for 2010/2011 -
group revenue increases to 35.2 million Euros
05.09.2012 / 17:04
---------------------------------------------------------------------
Jena, September 05th, 2012 - biolitec AG, Jena, listed on the Prime
Standard of the Frankfurt Stock Exchange (ISIN DE0005213409), has published
its unaudited financial statement for the fiscal year 2010/2011 in German
on its corporate website www.biolitec.de. Thus the company responds to some
shareholder's wishes who, on the Extraordinary General Meeting on August
30th 2012, declared themselves in favour of publishing the unaudited
statement. At the same time, biolitec wants to provide the greatest
possible transparency on the business development of the past years for its
shareholders.
Due to the unexpectedly demanding auditing work und the still not completed
audit of the annual financial statement, biolitec has not received a final
version of the annual financial statement yet. biolitec will publish the
final financial figures for the fiscal year 2010/2011 immediately after the
completion of the auditing work by the auditors of BDO.
biolitec already decided to publish the first three quarters of the fiscal
year 2011/2012 even without audited annual statement of accounts for
2010/2011, which has been closed with unaudited sales of 35.2 million
Euros.
In the fiscal year 2010/2011, the group revenue amounted to 35.2 million
Euros (previous year: 30.4 million Euros), which equals an increase of 16%.
Despite the positive development of sales, the group achieved a loss of
-5.169 million Euros from the operating business (EBIT -6.472 million
Euros) and was thus considerably under the previous year's level (previous
year: EBIT -45 thousand Euros). The reasons therefore are basically rooted
in a substantial rise of the general administrative expenses of -5.8
million Euros and additional currency losses of -1.5 million Euros. The
administrative expenses of the prior and singular corrections of the
US-American corporations' corporate values of 3.3 million Euros are
therewith included.
The sales for the Meditec segment were increased by 5.2 million Euros from
28.8 million Euros in the previous year to 34 million Euros. The sales in
the pharmaceuticals segment of 1.3 million Euros were slightly under the
previous year's level of 1.6 million Euros.
As in the past years, the reduction of inventory values has been
successfully continued (from 16.6 million Euros in the fiscal year
2009/2010 to 13.1 million Euros in 2010/2011). For the fiscal year
2011/2012, further reduction of inventories is planned.
The gross profit increased by 1.1 million Euros compared to the previous
year to Euro 20.6 million Euros. In the past financial year, biolitec's R&D
expenditures amounted to 3.2 million Euros (previous year: 3.6 million
Euros) or 9.2% of sales. Significant revenues of biolitec AG were achieved
in Europe and North America. The sales in North America amounted to 12.5
million Euros and were thus 7% higher than those in the previous fiscal
year. The sales in Europe reached 16.7 million Euros (previous fiscal year:
14.2 million Euros). In Asia/rest of the world biolitec could achieve a
significant increase of 41%.
The main generators of revenue were LIFE(TM), biolitec's laser treatment ofBPH, and the endoluminal laser treatment for veins (ELVeS(TM)). Due to the
launching of new, innovative products, as for example HeLP(TM) - a new
outpatient and pain-free treatment for the atrophy of haemorrhoidal
arteries - biolitec is able to compete and consolidate its position in key
markets worldwide.
The TWISTER(TM)-fiber defends its position as preferred treatment method
for the benign prostate hyperplasia and is still the first choice for
numerous specialists. The ELVeS(R) RADIAL-fiber has been highlighted in
several presentations and publications as state-of-the-art treatment for
veins.
The preliminary sales figures for the financial year 2011/2012 are also
already available and amount to 40.27 million Euros for the biolitec group.
biolitec AG expects growth to be sustained for the coming fiscal year
2012/13, biolitec expects growth to be sustained.
About biolitec(R)
biolitec(R) AG is one of the leading companies worldwide in the field of
medical laser treatments und the only provider that possesses all relevant
core competencies - photosensitizers, laser devices and optical fibres - in
the field of photodynamic therapy (PDT). Besides the laser treatment of
cancer with Foscan(R), biolitec(R) primarily researches on
minimally-invasive and gentle laser treatments and markets them. ELVeS
Radial(TM) (Endo Laser Vein System) the laser system is most often used
worldwide for the treatment of varicose veins. Ceralas(R) HPD laser therapy
enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in
urology. Gentle laser treatments in the fields of proctology, ENT,
orthopaedics, gynaecology as well as ophtalmology also belong to the
business field of biolitec(R). biolitec(R) is listed in the Prime Standard
(ISIN DE0005213409). Further information at www.biolitec.de.
Investor Relations
Jörn Gleisner
Telephone +49 (0) 69 / 959083-20
Telefax +49 (0) 69 / 959083-99
E-Mail: joern.gleisner(at)biolitec.com
The information does not constitute an offer of or an invitation by or on
behalf of biolitec AG or any of its subsidiaries to subscribe for or
purchase securities of biolitec AG or any of its subsidiaries.
In particular, the information contained does not constitute an offer of
securities for sale or solicitation of an offer to buy securities in the
United States of America.
End of Corporate News
---------------------------------------------------------------------
05.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: biolitec AG
Otto-Schott-Str.15
07745 Jena
Germany
Phone: +49 (0) 3641 519 53 0
Fax: +49 (0) 3641 519 53 33
E-mail: info(at)biolitec.de
Internet: www.biolitec.de
ISIN: DE0005213409
WKN: 521340
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
184322 05.09.2012
Themen in dieser Pressemitteilung:
biolitec-ag-publishes-unaudited-financial-statement-for-2010-2011
group-revenue-increases-to-35-2-million-euros
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Western Potash Corp. Submits Milestone Environmental Impact Statement and Provides Company UpdateDatum: 05.09.2012 - 17:04 Uhr
Sprache: Deutsch
News-ID 180627
Anzahl Zeichen: 4792
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: biolitec AG publishes unaudited financial statement for 2010/2011 - group revenue increases to 35.2 million Euros"
steht unter der journalistisch-redaktionellen Verantwortung von
biolitec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
